Copyright
©The Author(s) 2024.
World J Clin Cases. Jan 6, 2024; 12(1): 68-75
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.68
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.68
Group | Number of patients | Autogenous hemorrhage | Rash | Fever | Untoward effect |
Observation group | 33 | 1 (3.03) | 0 (0.00) | 0 (0.00) | 1 (3.03) |
Control group | 32 | 6 (18.75) | 0 (0.00) | 1 (3.12) | 7 (21.87) |
χ2 | - | - | - | - | 5.345 |
P value | - | - | - | - | 0.027 |
- Citation: Liu K, Li ZH. Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure. World J Clin Cases 2024; 12(1): 68-75
- URL: https://www.wjgnet.com/2307-8960/full/v12/i1/68.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i1.68